the hepatitis b virus is a major public health problem worldwide and is a major public health problem worldwide. the development of new therapies for coronaviruses is rapidly evolving and is now being challenged by the development of new therapies for corona viruses. we are now working on a new strategy to address this global health crisis and we are now working on the development of new molecules that target specific viral targets that fit well with our expertise. we are now working on a strategy to accelerate the development of new therapies for corona virus. we will continue to continue to advance our clinical development program for a new new capsid inhibitor, b-836, and a new new oral d-l1 compound that may be useful in reawakening patient's immune response to the human viral virus.